InsidersTradesSigma
Track the Anixa Biosciences Inc share price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Anixa Biosciences Inc has logged 75 insider filings. Market capitalisation: €116.4m. The latest transaction was reported on 3 August 2026 (Acquisition). Among the most active insiders: Titterton Lewis H jr. All data is accessible without an account.
75
Insider Decl.
n/a
Thresholds
€2m
55 ops.
Buy Volume
n/a
n/a
Sell Volume
53Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 August 2026
Declarations75 total
5,000 shares@ US$3.47Common StockSEC:0001493152-26-035751:0
Canonical exit: 29 Oct 2026 (T+90)
6,000 shares@ US$3.130.016% mcap6.1% of flowCommon StockSEC:0001493152-26-035122:0
5,428 shares@ US$3.460.016% mcap6.1% of flowCommon StockSEC:0001493152-26-035122:1
5,000 shares@ US$3.440.014% mcap0.6% of flowCommon StockSEC:0001493152-26-034952:0
Canonical exit: 25 Oct 2026 (T+90)
3,000 shares@ US$3.730.0089% mcap0.4% of flowCommon StockSEC:0001493152-26-034723:0
Canonical exit: 22 Oct 2026 (T+90)
3,188 shares@ US$3.370.0085% mcap0.3% of flowCommon StockSEC:0001493152-26-034772:0
Canonical exit: 25 Oct 2026 (T+90)
5,000 shares@ US$3.460.015% mcap0.6% of flowCommon StockSEC:0001493152-26-034027:0
Canonical exit: 18 Oct 2026 (T+90)
12,000 shares@ US$3.470.036% mcap2.9% of flowCommon StockSEC:0001493152-26-033949:0
Canonical exit: 18 Oct 2026 (T+90)
2,797 shares@ US$3.280.0077% mcap0.7% of flowCommon StockSEC:0001493152-26-033461:0
Canonical exit: 13 Oct 2026 (T+90)
5,000 shares@ US$3.040.014% mcap0.5% of flowCommon StockSEC:0001493152-26-032961:0
Canonical exit: 8 Oct 2026 (T+90)
2,836 sharesCommon StockSEC:0001493152-26-029030:0
Canonical exit: 14 Sept 2026 (T+90)
21,000 sharesCommon StockSEC:0001493152-26-028827:0
Canonical exit: 10 Sept 2026 (T+90)
10,000 shares@ US$3.0410.7% of flowCommon StockSEC:0001493152-26-004148:0
Canonical exit: 28 Apr 2026 (T+90)
16,000 shares@ US$2.922.6% of flowCommon StockSEC:0001493152-25-027904:0
200,000 shares@ US$2.9219.0% of flowCommon StockSEC:0001493152-25-020322:0
10,000 shares@ US$3.082.2% of flowCommon StockSEC:0001641172-25-022000:0
Canonical exit: 29 Oct 2025 (T+90)
5,000 shares@ US$3.160.6% of flowCommon StockSEC:0001641172-25-021679:0
Canonical exit: 28 Oct 2025 (T+90)
5,000 shares@ US$3.396.9% of flowCommon StockSEC:0001641172-25-020362:0
Canonical exit: 16 Oct 2025 (T+90)
10,000 shares@ US$3.141.8% of flowCommon StockSEC:0001641172-25-019587:0
Canonical exit: 9 Oct 2025 (T+90)
5,000 shares@ US$3.150.6% of flowCommon StockSEC:0001641172-25-018898:0
Canonical exit: 9 Oct 2025 (T+90)
10,000 shares@ US$2.851.2% of flowCommon StockSEC:0001641172-25-013724:0
Canonical exit: 2 Sept 2025 (T+90)
5,000 shares@ US$2.824.1% of flowCommon StockSEC:0001493152-25-004108:0
Canonical exit: 28 Apr 2025 (T+90)
2,000 shares@ US$2.910.4% of flowCommon StockSEC:0001493152-25-003733:0
Canonical exit: 23 Apr 2025 (T+90)
2,000 shares@ US$3.010.4% of flowCommon StockSEC:0001493152-25-003330:0
Canonical exit: 22 Apr 2025 (T+90)
6,000 shares@ US$2.591.0% of flowCommon StockSEC:0001493152-25-003157:0
Canonical exit: 21 Apr 2025 (T+90)
25 of 75 declarations
关于 Anixa Biosciences Inc
Anixa Biosciences Inc. 是一家总部位于美国的生物技术公司，在纳斯达克上市，股票代码为 ANIX。对于法语投资者而言，它符合临床阶段肿瘤生物技术公司的特征，而非商业制药公司：其投资案例主要取决于科学执行、临床结果、监管进展和战略合作伙伴关系。该公司总部位于加利福亚州圣何塞，地处美国最活跃的生物技术和风险投资生态系统之一。Anixa 的公司根源可追溯到 1982 年在特拉华州注册成立，该公司后来于 2018 年更名为 Anixa Biosciences，并将其重点放在癌症相关技术上。（[anixa.com](https://www.anixa.com/?utm_source=openai)） Anixa 的商业模式围绕高度集中的肿瘤创新而建立。其治疗产品组合包括一项卵巢癌免疫治疗项目，该项目基于一种名为 CER-T 的新型 CAR-T 方法，与 Moffitt 癌症中心合作开发。同时，该公司通过与 Cleveland Clinic 合作，推进一个旨在预防和治疗乳腺癌（尤其是三阴性乳腺癌）以及卵巢癌的疫苗平台。管理层还描述了额外的“退化组织特异性蛋白”疫苗项目，这些项目最终可能扩展到其他难治性癌症，如肺癌、结肠癌和前列腺癌。（[anixa.com](https://www.anixa.com/about?utm_source=openai)） 从竞争角度来看，Anixa 仍处于早期阶段，没有上市产品特许经营权。因此，其定位最好理解为一家小型临床创新公司，在竞争激烈的肿瘤研究领域中竞争。该公司的差异化来自于其平台的科学新颖性、围绕其疫苗和细胞疗法概念的知识产权，以及其学术和临床合作伙伴的信誉。这使得该股票对试验结果和融资条件高度敏感，同时如果其中一个项目成功推进，也具有显著的上涨空间。（[anixa.com](https://www.anixa.com/about?utm_source=openai)） 近期发展具有建设性。2025 年，Anixa 报告了其研究性乳腺癌疫苗的积极 1 期数据，称已达到关键主要终点并观察到免疫反应，支持向 2 期开发迈进。该公司还宣布与 VERDI Solutions 签署意向书，为癌症患者开发个性化和现成的肽疫苗。2026 年，Anixa 强调了其正在进行的卵巢癌 CAR-T 1 期研究中令人鼓舞的生存观察结果，并披露其乳腺癌疫苗技术获得了墨西哥专利保护。（[ir.anixa.com](https://ir.anixa.com/press-releases/detail/1107/anixa-biosciences-announces-positive-phase-1-data-for?utm_source=openai)） 总体而言，Anixa Biosciences Inc. 是一家在美国纳斯达克上市的生物技术公司，拥有明确的肿瘤学任务和以研究为主的特点。其地理足迹仍主要以美国为中心，但其知识产权和合作战略可能随着时间的推移支持更广泛的国际相关性。对于投资者而言，该名称代表了对癌症免疫疗法和疫苗开发的高风险、高回报敞口，其价值创造与临床里程碑而非当前运营规模相关。
